NEW YORK (GenomeWeb) – A subset of solid tumors containing PDL1 amplifications appear more prone to respond to immune checkpoint blockade immunotherapy, even in the absence of high PD-L1 protein expression, microsatellite instability (MSI), or enhanced tumor mutational burden (TMB).